With $39B in cash and biosim threats looming, could Amgen use a deal? Executives say not yet
admin 26th July 2017 Uncategorised 0Riding a strong performance from Enbrel and a few other meds, Amgen beat revenue expectations in second-quarter results released late Tuesday. But with “nothing significantly positive happening,” as one analyst put it, and Amgen’s $39 billion in cash, some market watchers are thinking M&A.
More: With B in cash and biosim threats looming, could Amgen use a deal? Executives say not yet
Source: fierce